At Innova Medical Group, we believe that innovation enables the development of ever faster screening methods and thus contributes to everyone living longer in better health.

Innova Medical Group is among the first in the medical technology field to offer a rapid antigen test that meets the highest standards of quality and accuracy for COVID-19 screening. Because Innova’s high standards ensures reproducible performance in large-scale production, in less than two years, more than two and a half billion units will have been distributed worldwide.

Innova Medical Group supports and partners with academic and private institutions in the development of technological and industrial advancements. As business and technological maturity are reached, these innovations are commercialized and scaled by Innova Medical Group with the aim of making them accessible and available to everyone, boosting their availability via our worldwide distribution network.

Several products, not yet available in France, are already offered in several countries around the world:

  • The combined SARS-CoV-2 and Influenza A and/or B self-test allows for the detection of SARS-CoV-2 and Influenza A and/or B antigens in less than 15 minutes through a simple, non-invasive and painless nasal swab.

  • The SARS-CoV-2 Saliva Self-Test, which is over 99% accurate, provides qualitative detection of SARS-CoV-2 antigen in a simple saliva sample.

  • The SARS-CoV-2 serological self-test qualitatively detects the presence of IgG anti-S and anti-RBD antibodies in a blood capillary sample.

The first-of-its-kind professional care solution for the quantitative measurement of immunity levels: ” Innova AttoBench System ” and its test ” Innova CovDImmune “.

The “Innova AttoBench System” and its immunity test “ Innova CovDImmune Test ” quantitatively evaluates in 7 minutes the concentration of total IgG antibodies directed against:

  • Nucleocapsid protein (N) indicating past exposure to the virus
  • Spike protein (S) indicating past infection or response to vaccination
  • Spike Omicron (SO) variant protein, indicating past infection or response to vaccination
  • The receptor binding domain (RBD)

The test also measures C-reactive protein and is currently performed on venous blood for greater accuracy.

This revolutionary solution allows healthcare professionals to offer patients a solution with no equivalent on the market and, thanks to an algorithm based on the concentration of antibodies directed against protein S, to evaluate the number of days remaining before the loss of immunity.

The persons tested will thus be able to know if they are among the 5% to 10% of individuals who do not produce antibodies. They will also be able to check whether their natural immunity level is sufficient or whether they need to plan a booster vaccination, and when.

All these questions can be answered with our new “Innova AttoBench System” and the “Innova CovDImmune Test”.